RT Journal Article
SR Electronic
T1 Curcumin dually inhibits both mTOR and NF-κB pathways through a crossed PI3K/Akt/IKK signaling axis in adenoid cystic carcinoma
JF Molecular Pharmacology
JO Mol Pharmacol
FD American Society for Pharmacology and Experimental Therapeutics
SP mol.110.066910
DO 10.1124/mol.110.066910
A1 Zhi-Jun Sun
A1 Gang Chen
A1 Wei Zhang
A1 Xiang Hu
A1 Yang Liu
A1 Qian Zhou
A1 Ling-Xin Zhu
A1 Yi-Fang Zhao
YR 2010
UL http://molpharm.aspetjournals.org/content/early/2010/10/19/mol.110.066910.abstract
AB Adenoid cystic carcinoma (ACC) is a highly malignant tumor that is generally unresponsive or only weakly responsive to the currently available antineoplastic agents. Thus novel therapeutic strategies and agents are urgently needed to treat this aggressive neoplasm. Curcumin, a component of turmeric (Curcuma longa), has been shown to have a diversity of anti-tumor activities. We show here that curcumin is a potent inhibitor of ACC progression in vitro and in vivo. Curcumin concentration-dependently inhibited the growth of ACC cells via induction of apoptosis. The ability of ACC cells to migrate/invade and induce angiogenesis was also significantly attenuated by curcumin, accompanied by the down-regulation of vascular endothelial growth factor (VEGF), matrix metalloproteinase-2 and -9. Moreover, our data also demonstrated that the inhibitory effects of curcumin on ACC cells were due to its dual-inhibition of both mammalian target of rapamycin (mTOR) and nuclear factor-κB (NF-κB) pathways through a crossed PI3K/Akt/IKK signaling axis. Most importantly, curcumin effectively prevented the in vivo growth and angiogenesis of ACC xenografts in nude mice, as revealed by the induction of cell apoptosis and reduction of microvessel density (MVD) in tumor tissues. Additionally, we further assessed the nature activation status of both mTOR and NF-κB pathways in ACC tissues, and confirmed the concurrent high activation of these two pathways in ACC for the first time. Taken together, our findings suggest that further clinical investigation is warranted to apply curcumin as a novel chemotherapeutic regimen for ACC due to its dual-suppression of both mTOR and NF-κB pathways.